

# This Week's **Top** Industry News

Provided as a service to DCAT member companies each Friday.

**BUSY WEEK?** Here are the **TOP INDUSTRY NEWS** stories you might have missed, as selected by DCAT Editorial Director *Patricia Van Arnum*.

**1. [Sanofi, Boehringer Ingelheim Plan Swap of Animal Health and Consumer Healthcare Businesses](#)**

Sanofi and Boehringer Ingelheim have entered into exclusive negotiations to swap businesses. The proposed transaction would consist of an exchange of Sanofi's animal health business (Merial) with an enterprise value of EUR 11.4 billion (\$12.4 billion) and Boehringer Ingelheim's consumer healthcare business (excluding China) with an enterprise value of EUR 6.7 billion (\$7.3 billion) as well as a gross cash payment from Boehringer Ingelheim to Sanofi of EUR 4.7 billion (\$5.1 billion). [Read More](#)

**2. [AstraZeneca To Acquire Majority Stake in Acerta in \\$4 Billion Deal](#)**

AstraZeneca has agreed to take a majority equity stake in Acerta Pharma, a privately owned biopharmaceutical company based in the Netherlands and US, in a deal valued up to \$4 billion. Acerta's key product is a cancer therapy, an oral Bruton's tyrosine kinase inhibitor, acalabrutinib. [Read More](#)

**3. [AstraZeneca Outlines Investments in China](#)**

AstraZeneca has announced a range of strategic initiatives in China, the company's second largest market globally and a key growth platform. Its plans include a development and launch facility for small molecules, a new global hub for pharmaceutical development, and a partnership with WuXi AppTec for biologics manufacturing. [Read More](#)

**4. [GSK, BMS Ink \\$1.5 Billion HIV Drug Deal](#)**

GlaxoSmithKline's global HIV business, ViiV Healthcare, has reached two separate agreements with Bristol-Myers Squibb (BMS) to acquire BMS' late-stage HIV R&D assets and BMS' portfolio of preclinical and discovery-stage HIV research assets in a deal valued up to \$1.5 billion. [Read More](#)

**5. [Gilead, Galapagos Sign \\$2 Billion Partnership for Anti-Inflammatory Drug](#)**

Gilead Sciences and Galapagos NV, a Belgian biopharmaceutical company, have formed a global partnership for the development and commercialization of the JAK1-selective inhibitor, filgotinib, for treating inflammatory disease indications in a deal valued up to \$2 billion. [Read More](#)

**6. [AstraZeneca Completes Acquisition of ZS Pharma](#)**

AstraZeneca has completed its previously announced tender offer for all of the outstanding shares of ZS Pharma, a biopharmaceutical company based in San Mateo, California, for \$2.7 billion, and the subsequent acquisition of the company. [Read More](#)

**7. [BMS Completes Acquisition of Cardioxyl Pharmaceuticals](#)**

Bristol-Myers Squibb has completed its previously announced \$2.1 billion acquisition of Cardioxyl Pharmaceuticals, Inc., a private biotechnology company focused on the discovery and development

of cardiovascular drugs. [Read More](#)

## 8. [Lilly, BI Gain US Approval for Long-Acting Insulin](#)

The FDA has approved Eli Lilly and Company's and Boehringer Ingelheim's Basaglar (insulin glargine injection) 100 units/mL, a long-acting insulin with an identical amino acid sequence to Sanofi's Lantus, another U-100 insulin glargine. Lantus was Sanofi's top-selling drug in 2014 with sales of EUR 6.3 billion (\$6.8 billion). [Read More](#)

## 9. [Study Points to Shortage of Pharmaceutical Inspectors in India](#)

The Associated Chambers of Commerce & Industry of India and the research firm, RNCOS, have issued a report highlighting a shortage of inspectors for the pharmaceutical industry in the country. According to the report, India has only 1,500 inspectors to inspect more than 10,000 plants engaged in pharmaceutical manufacturing. [Read More](#)

## 10. [AstraZeneca Forms Pact to Improve Biologics Production](#)

AstraZeneca has formed a three-year collaboration to develop new technologies for biologics production and to identify new targets for disease research in the area of the Secretome, a new area for protein research. [Read More](#)

*The DCAT organization is happy to provide this service to its members each Friday.  
The December 18th issue of Top Industry News will be our last issue in 2015.  
We will be back in January with the January 8, 2016 issue.  
Have a Happy Holiday and Happy New Year!*

---

### About Top Industry News

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



The Drug, Chemical & Associated Technologies Association (DCAT) is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

### [Forward this email](#)



This email was sent to [esanders@dcat.org](mailto:esanders@dcat.org) by [dcatnews@dcat.org](mailto:dcatnews@dcat.org) | [Update Profile/Email Address](#) | Rapid removal with [SafeUnsubscribe™](#) | [About our service provider.](#)